Senti Biosciences Statistics
Share Statistics
Senti Biosciences has 4.59M shares outstanding. The number of shares has increased by -89.72% in one year.
| Shares Outstanding | 4.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -89.99% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.88M |
| Failed to Deliver (FTD) Shares | 38 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 65.09K, so 1.42% of the outstanding shares have been sold short.
| Short Interest | 65.09K |
| Short % of Shares Out | 1.42% |
| Short % of Float | 2.26% |
| Short Ratio (days to cover) | 3.27 |
Valuation Ratios
The PE ratio is -0.32 and the forward PE ratio is -3.02.
| PE Ratio | -0.32 |
| Forward PE | -3.02 |
| PS Ratio | 11.44 |
| Forward PS | 1.1 |
| PB Ratio | 0.44 |
| P/FCF Ratio | -0.45 |
| PEG Ratio | n/a |
Enterprise Valuation
Senti Biosciences Inc. has an Enterprise Value (EV) of 31.03M.
| EV / Earnings | -0.33 |
| EV / Sales | 12.11 |
| EV / EBITDA | -0.51 |
| EV / EBIT | -0.33 |
| EV / FCF | -0.48 |
Financial Position
The company has a current ratio of 5.62, with a Debt / Equity ratio of 0.
| Current Ratio | 5.62 |
| Quick Ratio | 5.62 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.39% and return on capital (ROIC) is -88.67%.
| Return on Equity (ROE) | -1.39% |
| Return on Assets (ROA) | -0.78% |
| Return on Capital (ROIC) | -88.67% |
| Revenue Per Employee | 53.35K |
| Profits Per Employee | -1.94M |
| Employee Count | 48 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 45.81% in the last 52 weeks. The beta is 2.75, so Senti Biosciences 's price volatility has been higher than the market average.
| Beta | 2.75 |
| 52-Week Price Change | 45.81% |
| 50-Day Moving Average | 2.98 |
| 200-Day Moving Average | 3.06 |
| Relative Strength Index (RSI) | 57.88 |
| Average Volume (20 Days) | 2.27M |
Income Statement
In the last 12 months, Senti Biosciences had revenue of $2.56M and earned -$92.92M in profits. Earnings per share was $-16.01.
| Revenue | 2.56M |
| Gross Profit | -2.68M |
| Operating Income | -92.73M |
| Net Income | -92.92M |
| EBITDA | -61.34M |
| EBIT | -92.73M |
| Earnings Per Share (EPS) | -16.01 |
Balance Sheet
The company has $35.93M in cash and $37.67M in debt, giving a net cash position of -$1.74M.
| Cash & Cash Equivalents | 35.93M |
| Total Debt | 37.67M |
| Net Cash | -1.74M |
| Retained Earnings | -244.34M |
| Total Assets | 57.72M |
| Working Capital | 8.32M |
Cash Flow
In the last 12 months, operating cash flow was -$52.40M and capital expenditures -$12.04M, giving a free cash flow of -$64.43M.
| Operating Cash Flow | -52.40M |
| Capital Expenditures | -12.04M |
| Free Cash Flow | -64.43M |
| FCF Per Share | -14.52 |
Margins
Gross margin is -104.76%, with operating and profit margins of -3.62K% and -3.63K%.
| Gross Margin | -104.76% |
| Operating Margin | -3.62K% |
| Pretax Margin | -3.26K% |
| Profit Margin | -3.63K% |
| EBITDA Margin | -2.40K% |
| EBIT Margin | -3.62K% |
| FCF Margin | -2.52K% |
Dividends & Yields
SNTI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -287.43% |
| FCF Yield | -252.1% |
Analyst Forecast
The average price target for SNTI is $12, which is 115.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12 |
| Price Target Difference | 115.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 18, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 18, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -10.26 |
| Piotroski F-Score | 2 |